ID
40803
Descripción
Study ID: 103933 Clinical Study ID: NKV103933 Study Title: A non-randomised, open label, two period cross-over study to determine the excretion balance and metabolic disposition of [14C]-GW679769, administered as single doses of an oral solution and an intravenous infusion to healthy male subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced Protocol ID: NKV103933 The eligibility to participate was determined during a screening visit within 21 days prior to first dosing day. The study consisted of two dosing periods, each consisting of predose visit, monitoring after dose administration and prior to discharge visit. Dosing periods were separated by a wash-out period of 43 days. This form has to be filled in during Treatment Period 2. Planned Timepoint: Day 1. Record any changes to the subject’s concomitant medications or any new medications taken since the last visit in the appropriate Concomitant Medications section. Review adverse events at 4 and 12 hours post-dose, in addition to any spontaneously reported AEs throughout the day. Record details of any new adverse events observed or reported by the subject or any changes to ongoing adverse events in the appropriate Non-Serious Adverse Events/Serious Adverse Event section.
Palabras clave
Versiones (1)
- 15/5/20 15/5/20 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
15 de mayo de 2020
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Study of Casopitant Pharmacokinetics in Healthy Males, NKV103933
Oral dose, Treatment Confirmation
- StudyEvent: ODM
Descripción
Investigational Product - Oral Dose Administration
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C1527415
Descripción
Fasting
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0015663
Descripción
Specification of quantities and time of food consumption
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C2983605
- UMLS CUI [1,2]
- C1265611
- UMLS CUI [2,1]
- C2983605
- UMLS CUI [2,2]
- C0040223
Descripción
Date of dose
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0011008
Descripción
Time of dose
Tipo de datos
time
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0040223
Descripción
Treatment Confirmation
Alias
- UMLS CUI-1
- C0087111
- UMLS CUI-2
- C0750484
Descripción
Therapeutic Procedure, Confirmation
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0750484
Descripción
Therapeutic Procedure, Wrong, Reason and justification
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C3827420
- UMLS CUI [1,3]
- C0566251
Similar models
Oral dose, Treatment Confirmation
- StudyEvent: ODM
C1527415 (UMLS CUI-2)
C1265611 (UMLS CUI [1,2])
C2983605 (UMLS CUI [2,1])
C0040223 (UMLS CUI [2,2])
C0178602 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0178602 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
C0750484 (UMLS CUI-2)
C0750484 (UMLS CUI [1,2])
C3827420 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,3])